10/570613

IAPS RCC'd PCT/PTO 2 8 FEB 20077

12/15/2008

Considered

PTO/S8/08. (04-03)
Approved for use through 04/03/2003. ONe 0651-0031
U.S. Patent and Trademant Office; U.S. DEPARTMENT OF COMMERCE.
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unitest contains a valid OMS control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary) of 2

Application Number Filing Date HEREWITH First Named Inventor Yoshida, et al 1621 Art Unit --- S. Kumar PREZP102US Examiner Name Attorney Docket Number

Chant	heet 1 of 2		Attorney Docket Number PREZP102US		
SHEEL	·				
				DOCUMENTS	I a Oli - Il When
Examiner Initials*	No.'		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passeges or Relevant Figures Appear
/SK/		Number-Kind Code ^{2 (Fancum)} US- 6,001,879	12/14/1999	Seitz, et al.	
		^{US-} 2005/0014700	01/20/2005	Boger	
1,	_	US- 4,315,766	02/16/1982	Hamprecht, et al.	
Ψ		US- 5,017,211	05/21/1991	Wenger, et al.	
		US-			
	 _	US-			
	\perp	US-		 	
	-				
	1	US-			

Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Peges, Columns, Lines, Where Relevant Pessages Or Relevant Figures Appear	⊤ 6
/SK/		Country Code ³ "Number ⁴ " Kind Code ³ (if known) JP 11-511442	10/05/1999	Bayer AG		V
/SK/		WO 03/022806	03/20/2003	Scripps Research		
0144	-	JP 55-141476	11/05/1980	BASF AG		Α
S ISK/		JP 02-501388	05/17/1990	F. Hoffmann		1
						⊢

Signature "EXAMINER: Initial if inference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optionsis). *See Kinds Cobes of USPTO Patent December 3. www.ingdo.gov or MPEP 90.104. *Either Clinica that issued the document, by the two-learner code (WPO 3.014. *Clinical Clinical Interval is assemble document, by the two-learner code (WPO 3.014. *Clinical Clinical Interval Interval

termission 1 americs.

This collection of thornalism is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to commission including glamen, preparing, and sustaining the compression of the confidential process. The confidential process of the confidential

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

/Shailendra Kumar/

^{**}Check Mark indicates English abstract of corresponding PCT Application**

^{**} A - indicates Japanese Patent Abstract **

10/570013

IAP9 Rec'd PCT/PTO 28 FEB 2005

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	re required to respond to a collection of information unless it contains a valid OMB control number Complete if Known			
Substitute for form 1449/PTO	Application Number			
INFORMATION DISCLOSURE	Filing Date	HEREWITH Yoshida, et al.		
STATEMENT BY APPLICANT	First Named Inventor			
	Art Unit		1621	
(Use as many sheets as necessary)	Examiner Name	S. Kumar		
Sheet 2 of 2	Attorney Docket Number	PREZP102US		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
7SK/		IWAKURA, et al., The Syntheses and Some Reactions of Isocyanatoalkanecarboxylic Acid Chlorides and Isocyanatobenzoyl Chlorides, J. Org. Chem., Vol. 31(1), p.142, 1966	
/SK/		BOGER, et al., Total Synthesis of Distamycin A and 2640 Analogues: A Solution-Phase Combinatorial Approach to the Discovery of New, Bioactive DNA Binding Agents and Development of a Rapid. High-Throughput Screen for Determining Rative DNA Am. Chem. Soc., Vii. 122(27). p. 6382, 2000	
/SK		International Search Report for PCT/JP2004/012416, November 30, 2004	
			-
	-		
		·	

Examiner Signature	/Shailendra Kumar/	Date Considered	12/15/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

considered, Incides copy of this form with next communication to applicant.

A pigeoniar, using actions designation unsurbar (optional). Applicant is to be loade a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPT) or process) as suggisted on. Confiderable is glowment by 53 U.S. C. 12 and 57 CFR 1.14. This collection is estimated to thus 120 minutes to complete, including gathering, preparing, and submitting the completed application form be the USPTO. Time will very depending upon the individual case. Any comments of the amount of time you require to complete the form and/or suggestions for reducing this burden, though the suffer load to the unit to the Common of the Common of time you capacition for the complete and the common of the common of the common of the common of time you cause to common of the com